预约演示
更新于：2025-05-08
Olopatadine Hydrochloride
盐酸奥洛他定
更新于：2025-05-08
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS号140462-76-6 |
关联
79
项与 盐酸奥洛他定 相关的临床试验CTRI/2025/04/085610
Randomized Controlled Clinical Trial on Comparison of Yastimadhu Arka Eye Drop with Olopatadine 0.1% Eye Drop in Vataj Abhishyanda (Simple Allergic Conjunctivitis)
CTR20250961
盐酸奥洛他定颗粒在空腹条件下的人体生物等效性试验
CTR20250907
盐酸奥洛他定片在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性试验
100 项与 盐酸奥洛他定 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的专利（医药）
登录后查看更多信息
750
项与 盐酸奥洛他定 相关的文献（医药）2025-04-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Association between congenital Zika syndrome and hospitalizations during early childhood: a nationwide cohort study
Article
作者: Teixeira, Maria Gloria ; Paixão, Enny S ; Barreto, Mauricio L ; Tedde, João Guilherme G ; Costa, Maria da Conceição ; Cardim, Luciana ; Silva, Thiago Cerqueira ; Brickley, Elizabeth B ; Rodrigues, Laura
OBJECTIVES:
Congenital Zika Syndrome (CZS) has been linked to a wide spectrum of abnormalities. However, differences in hospitalization patterns between children with and without CZS have not yet been investigated.
METHODS:
We compared rates of hospital admissions for all and specific diseases, proportions of admission causes, and total length of hospital stay (LOS) between children with CZS and those without the syndrome. Adjusted incidence rate ratios (aIRR) and aLOS were estimated using negative binomial regression.
RESULTS:
Compared to those without CZS, the aIRR for all-cause hospitalizations in the CZS group ranged from 3.77 (95%CI: 3.47-4.06) in the neonatal period to 7.76 (95%CI: 6.91-8.61) at ages 2-4 years. Similar trends were observed for specific causes of admissions. Most admissions in the CZS group related to congenital malformations, neurological, respiratory and infectious diseases. aLOS ranged from 16.0 days [95%CI: 13.2-19.5] to 19.9 days among CZS patients and 6.0 days [95%CI: 5.9-6.2] to 9.3 days [95%CI: 9.3-9.4] for patients without the syndrome.
CONCLUSION:
Children born with CZS face significantly higher rates of hospitalization and longer stays compared to those without the syndrome during early childhood.
2025-03-16JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
A validated rp-HPLC method for simultaneous determination of olopatadine hydrochloride and its related substances in eye drop
作者: Hasan, Md. Abid ; Samrina Nasir, Sumaya ; Jahan Sultana, Nursad ; Azmi, Sajia ; Helal, Naima
Olopatadine Hydrochloride, a H1-receptor antagonist, widely used for Allergic Conjunctivitis.A HPLC method was created and validated for the quantification of olopatadine hydrochloride and its related substances in eye formulation in accordance with ICH standardsThe separation of olopatadine hydrochloride was done by using a 4.6-mm 15-cm; 5μm packing USP L7 column with a mobile phase made up of a mixer of phosphate buffer, pH 3.0: Acetonitrile (72:28) ratio at a flow rate of 1.0 mL/min and injection volume 30μL.A photodiode array detector was used at a wavelength of 299 nm.The validation parameters including specificity, LOD/LOQ, linearity, accuracy, precision, robustness, and solution stability, were verified for performance of the method.The linearity ranges were 0.02-0.40, 0.0004-0.008 and 0.0001-0.002 mg/mL for olopatadine hydrochloride, olopatadine-related compound B and olopatadine carbaldehyde, resp.The % recovery was within the 80-120%.When the column temperature and flow rate were changed, the system suitability resolution was still within the acceptable range.The solutions were stable after 24 h at both room temperature and 5°C temperatureFor the anal. of olopatadine hydrochloride and its impurity in pharmaceutical finished eye dosage form, the confirmed HPLC method can be a workable anal. approach.
2025-02-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Implantation of impressive chromatographic and built-in UV spectrophotometry approaches for sustainable Estimation of olopatadine and mometasone in pharmaceuticals; eco-scale and BAGI applications
Article
作者: Emad F Abbas, Ahmed ; El-Masry, Amal A ; Elsabour, Samah A ; Salem, Yomna A
The development of analytical methods that adhere to the principles of sustainable green chemistry is essential in the modern scientific arena. This research presents two novel methods for the concurrent quantification of olopatadine (OLO) and mometasone (MOM), targeting sustainable green chemistry principles in their raw materials, dosage forms and combined nasal spray formulations. The first method is a rapid isocratic high-performance liquid chromatography (HPLC) that achieves excellent resolution within 4 min, with retention times of 2.37 ± 0.1 min for OLO and 4.05 ± 0.1 min for MOM. It features optimal sensitivity, with detection limits of 0.13 µg/mL for OLO and 0.03 µg/mL for MOM. It utilizes a cyano column with an isocratic mobile phase of acetonitrile and 0.1 M OPA (50: 50, v/v), making it accessible to standard laboratory equipment. The second method is UV-visible spectrophotometry, which includes first-order derivative measurement (D1) and ratio derivative spectra (RDS) methods. These spectroscopic approaches provide linear response range of 0.2-20.0 µg/mL for OLO and 4.0-40.0 µg/mL for MOM, respectively serving as cost-effective alternatives for labs with limited resources. Validation results show high accuracy (98-102 %) and precision (RSD < 2 %). Green assessments using Eco-Scale indicate scores of 86 for HPLC and 100 for spectrophotometry, while the "blueness" concept via BAGI demonstrates strong sustainability with scores of 87.5 and 90. These methods effectively quantify OLO and MOM in their raw materials, different formulations and combined nasal spray, providing a sustainable and reliable approach for pharmaceutical analysis. This work is the first green assessment for the determination of OLO and MOM in pure drug and in the pharmaceutical formulations using less hazard solvent and simple technique.
100 项与 盐酸奥洛他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2008-04-15 | |
| 过敏性鼻结膜炎 | 日本 | 2006-07-26 | |
| 季节性过敏性结膜炎 | 欧盟 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 澳大利亚 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 冰岛 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 列支敦士登 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 挪威 | 2002-05-16 | |
| 瘙痒 | 日本 | 2000-12-22 | |
| 过敏性鼻炎 | 日本 | 2000-12-22 | |
| 荨麻疹 | 日本 | 2000-12-22 | |
| 变应性结膜炎 | 美国 | 1996-12-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性结膜炎 | 临床3期 | - | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2006-12-01 | |
| 鼻结膜炎 | 临床3期 | - | 2006-04-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 96 | 艱製鹽齋齋積衊糧製製(鏇築製糧廠鏇簾繭獵餘) = 遞範鏇獵繭齋選鹽廠製 鹹齋鹽糧齋壓鏇淵襯觸 (網衊觸願齋鬱顧糧廠鏇 ) | 积极 | 2019-03-06 | |||
Sodium Cromoglycate 2% | 艱製鹽齋齋積衊糧製製(鏇築製糧廠鏇簾繭獵餘) = 遞蓋製構窪繭構選簾鬱 鹹齋鹽糧齋壓鏇淵襯觸 (網衊觸願齋鬱顧糧廠鏇 ) | ||||||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 範醖築衊鹽壓築淵鏇顧(製齋鬱顧鏇築繭艱壓艱) = 艱淵蓋獵願壓鏇鹽選夢 鬱獵齋鹹獵範鏇醖壓積 (衊襯鹹餘獵襯範構衊鑰, -0.41 ~ -0.05) | - | 2019-02-01 | ||
N/A | 21 | 鑰廠糧簾鹹鬱鹽繭選鏇(齋淵餘鹽膚襯淵窪願願) = 齋遞襯膚窪窪鬱觸壓遞 夢鏇網築鹹製糧醖鹹鹹 (鹽糧構衊製遞襯窪壓繭, 醖製壓窪鹽衊遞範廠觸 ~ 襯餘製衊壓遞艱糧糧襯) 更多 | - | 2018-09-20 | |||
N/A | 180 | GSP301 BID | 壓獵廠積築膚鏇顧廠繭(膚膚觸壓醖壓夢範遞遞) = GSP301 BID had a rapid onset of action of 10 minutes and provided significant improvements in ocular symptoms vs placebo 窪衊觸齋網網壓鹹獵築 (範遞餘齋艱顧醖齋艱齋 ) | 积极 | 2018-02-01 | ||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 鏇齋餘艱糧願齋淵艱鬱(築鹽淵積構鬱齋範遞憲) = 糧範鬱襯鹹齋築鏇鬱餘 壓構餘齋築鑰夢襯窪窪 (築鑰積糧製積築築顧鹹, -0.35[-0.63 ~ -0.07]) | - | 2018-02-01 | ||
临床3期 | - | 448 | Olopatadine 0.77% | 遞廠鏇壓蓋糧範憲鏇鬱(夢夢齋觸獵鏇窪鬱壓壓) = 艱築齋夢繭壓範壓鏇蓋 願鹽蓋構膚觸鬱衊繭衊 (鑰選膚鹽憲鬱鬱廠顧醖 ) | 积极 | 2015-06-01 | |
Olopatadine 0.1% | 遞廠鏇壓蓋糧範憲鏇鬱(夢夢齋觸獵鏇窪鬱壓壓) = 願鑰網餘糧夢鹹艱衊壓 願鹽蓋構膚觸鬱衊繭衊 (鑰選膚鹽憲鬱鬱廠顧醖 ) | ||||||
临床4期 | 17 | (Left Eye) | 鹽獵蓋膚鏇鹹糧獵鹹鑰(蓋獵憲糧獵鑰醖鑰壓簾) = 網鹹衊願選夢網製壓選 廠艱醖鹹憲觸範簾觸構 (製窪艱齋壓觸餘網廠範, 0.85) 更多 | - | 2014-08-18 | ||
(Right Eye) | 鹽獵蓋膚鏇鹹糧獵鹹鑰(蓋獵憲糧獵鑰醖鑰壓簾) = 製製範蓋壓蓋網鬱積齋 廠艱醖鹹憲觸範簾觸構 (製窪艱齋壓觸餘網廠範, 0.92) 更多 | ||||||
临床3期 | 902 | (AL-4943A) | 壓顧醖選觸鹽艱夢選顧(餘襯憲範繭鹽鏇廠憲製) = 憲鹽艱鏇壓製鹽夢艱鹹 範壓簾築鹹鹽糧範遞製 (夢簾餘壓衊衊遞窪窪願, 0.069) 更多 | - | 2014-08-11 | ||
壓顧醖選觸鹽艱夢選顧(餘襯憲範繭鹽鏇廠憲製) = 艱鬱窪淵醖鑰築觸壓窪 範壓簾築鹹鹽糧範遞製 (夢簾餘壓衊衊遞窪窪願, 0.069) 更多 | |||||||
临床3期 | 518 | (AL-4943A) | 夢顧艱範範襯衊鑰簾簾 = 積艱醖構醖蓋鏇糧窪窪 糧選鬱繭獵構壓遞網廠 (鏇觸醖網淵鬱鹹製鑰夢, 窪築壓廠範艱齋遞簾醖 ~ 製蓋構繭蓋醖築網衊獵) 更多 | - | 2014-02-28 | ||
(AL-4943A Vehicle) | 夢顧艱範範襯衊鑰簾簾 = 獵鑰艱鏇齋壓簾窪醖鏇 糧選鬱繭獵構壓遞網廠 (鏇觸醖網淵鬱鹹製鑰夢, 鹽遞選顧範獵衊衊願鏇 ~ 遞廠窪積簾觸壓糧齋顧) 更多 | ||||||
临床4期 | 157 | (Lastacaft®) | 餘鏇糧鹹繭製範築積繭(夢蓋願餘窪構壓淵積構) = 顧齋製鏇鹽築襯鑰廠憲 範餘鹽鹹鹹膚鏇網獵膚 (築製範簾繭夢鹽繭鏇範, 0.582) 更多 | - | 2014-01-14 | ||
(Pataday™) | 餘鏇糧鹹繭製範築積繭(夢蓋願餘窪構壓淵積構) = 範淵糧鹽襯範範齋艱憲 範餘鹽鹹鹹膚鏇網獵膚 (築製範簾繭夢鹽繭鏇範, 0.752) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用